Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy

Brandon S. Imber; Michel Sadelain; Carl DeSelm; Connie Batlevi; Renier J. Brentjens; Parastoo B. Dahi; Sergio Giralt; Jae H. Park; Craig Sauter; Michael Scordo; Gunjan Shah; Miguel Angel Perales; M. Lia Palomba; Joachim Yahalom

doi:10.1111/bjh.16541

Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy

Brandon S. Imber, Michel Sadelain, Carl DeSelm, Connie Batlevi, Renier J. Brentjens, Parastoo B. Dahi, Sergio Giralt, Jae H. Park, Craig Sauter, Michael Scordo, Gunjan Shah, Miguel Angel Perales, M. Lia Palomba, Joachim Yahalom

Research output: Contribution to journal › Article › peer-review

56 Scopus citations

Abstract

Radiotherapy is potentially an important salvage strategy post-chimeric antigen receptor T cell therapy (CART), but limited data exist. We reviewed 14 patients treated with salvage radiation post-CART progression (SRT). Most received SRT for first post-CART relapse (71%) to sites previously PET-avid pre-CART (79%). Median overall survival (OS) post-SRT was 10 months. Post-SRT, six localized relapses achieved 100% response (3 = complete, 3 = partial), with improved freedom from subsequent relapse (P = 0·001) and OS (P = 0·004) compared to advanced stage relapses. Three were bridged to allogeneic transplantation; at analysis, all were alive/NED. SRT has diverse utility and can integrate with novel agents or transplantation to attempt durable remissions.

Original language	English
Pages (from-to)	45-51
Number of pages	7
Journal	British Journal of Haematology
Volume	190
Issue number	1
DOIs	https://doi.org/10.1111/bjh.16541
State	Published - Jul 1 2020

Keywords

CAR T cells
chimeric antigen receptor T cells
diffuse large B cell lymphoma
radiotherapy
relapsed/refractory
salvage therapy

Access to Document

10.1111/bjh.16541

Cite this

Imber, B. S., Sadelain, M., DeSelm, C., Batlevi, C., Brentjens, R. J., Dahi, P. B., Giralt, S., Park, J. H., Sauter, C., Scordo, M., Shah, G., Perales, M. A., Palomba, M. L., & Yahalom, J. (2020). Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy. British Journal of Haematology, 190(1), 45-51. https://doi.org/10.1111/bjh.16541

@article{91133645aa3040ac8f14466b727d7b40,

title = "Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy",

abstract = "Radiotherapy is potentially an important salvage strategy post-chimeric antigen receptor T cell therapy (CART), but limited data exist. We reviewed 14 patients treated with salvage radiation post-CART progression (SRT). Most received SRT for first post-CART relapse (71%) to sites previously PET-avid pre-CART (79%). Median overall survival (OS) post-SRT was 10 months. Post-SRT, six localized relapses achieved 100% response (3 = complete, 3 = partial), with improved freedom from subsequent relapse (P = 0·001) and OS (P = 0·004) compared to advanced stage relapses. Three were bridged to allogeneic transplantation; at analysis, all were alive/NED. SRT has diverse utility and can integrate with novel agents or transplantation to attempt durable remissions.",

keywords = "CAR T cells, chimeric antigen receptor T cells, diffuse large B cell lymphoma, radiotherapy, relapsed/refractory, salvage therapy",

author = "Imber, {Brandon S.} and Michel Sadelain and Carl DeSelm and Connie Batlevi and Brentjens, {Renier J.} and Dahi, {Parastoo B.} and Sergio Giralt and Park, {Jae H.} and Craig Sauter and Michael Scordo and Gunjan Shah and Perales, {Miguel Angel} and Palomba, {M. Lia} and Joachim Yahalom",

note = "Publisher Copyright: {\textcopyright} 2020 British Society for Haematology and John Wiley & Sons Ltd",

year = "2020",

month = jul,

day = "1",

doi = "10.1111/bjh.16541",

language = "English",

volume = "190",

pages = "45--51",

journal = "British Journal of Haematology",

issn = "0007-1048",

number = "1",

}

Imber, BS, Sadelain, M, DeSelm, C, Batlevi, C, Brentjens, RJ, Dahi, PB, Giralt, S, Park, JH, Sauter, C, Scordo, M, Shah, G, Perales, MA, Palomba, ML & Yahalom, J 2020, 'Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy', British Journal of Haematology, vol. 190, no. 1, pp. 45-51. https://doi.org/10.1111/bjh.16541

TY - JOUR

T1 - Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy

AU - Imber, Brandon S.

AU - Sadelain, Michel

AU - DeSelm, Carl

AU - Batlevi, Connie

AU - Brentjens, Renier J.

AU - Dahi, Parastoo B.

AU - Giralt, Sergio

AU - Park, Jae H.

AU - Sauter, Craig

AU - Scordo, Michael

AU - Shah, Gunjan

AU - Perales, Miguel Angel

AU - Palomba, M. Lia

AU - Yahalom, Joachim

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Radiotherapy is potentially an important salvage strategy post-chimeric antigen receptor T cell therapy (CART), but limited data exist. We reviewed 14 patients treated with salvage radiation post-CART progression (SRT). Most received SRT for first post-CART relapse (71%) to sites previously PET-avid pre-CART (79%). Median overall survival (OS) post-SRT was 10 months. Post-SRT, six localized relapses achieved 100% response (3 = complete, 3 = partial), with improved freedom from subsequent relapse (P = 0·001) and OS (P = 0·004) compared to advanced stage relapses. Three were bridged to allogeneic transplantation; at analysis, all were alive/NED. SRT has diverse utility and can integrate with novel agents or transplantation to attempt durable remissions.

AB - Radiotherapy is potentially an important salvage strategy post-chimeric antigen receptor T cell therapy (CART), but limited data exist. We reviewed 14 patients treated with salvage radiation post-CART progression (SRT). Most received SRT for first post-CART relapse (71%) to sites previously PET-avid pre-CART (79%). Median overall survival (OS) post-SRT was 10 months. Post-SRT, six localized relapses achieved 100% response (3 = complete, 3 = partial), with improved freedom from subsequent relapse (P = 0·001) and OS (P = 0·004) compared to advanced stage relapses. Three were bridged to allogeneic transplantation; at analysis, all were alive/NED. SRT has diverse utility and can integrate with novel agents or transplantation to attempt durable remissions.

KW - CAR T cells

KW - chimeric antigen receptor T cells

KW - diffuse large B cell lymphoma

KW - radiotherapy

KW - relapsed/refractory

KW - salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=85080953208&partnerID=8YFLogxK

U2 - 10.1111/bjh.16541

DO - 10.1111/bjh.16541

M3 - Article

C2 - 32135029

AN - SCOPUS:85080953208

SN - 0007-1048

VL - 190

SP - 45

EP - 51

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this